Exploration the Mechanism of Ba-Duan-Jin in the Treatment of Fibromyalgia Based on Brain-gut Axis - Trial NCT06410430
Access comprehensive clinical trial information for NCT06410430 through Pure Global AI's free database. This phase not specified trial is sponsored by Guang'anmen Hospital of China Academy of Chinese Medical Sciences and is currently Recruiting. The study focuses on Fibromyalgia. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Timeline & Enrollment
N/A
Jan 31, 2024
Jun 30, 2024
Primary Outcome
The change of the Visual Analogue Scale (VAS) for pain from baseline,The change of Tender Point Count (TPC) from baseline
Summary
To investigate the mechanism by Ba-Duan-Jin in the treatment of fibromyalgia. Twenty eligible
 fibromyalgia patients were selected, and were trained and guided online by an experienced
 Ba-Duan-Jin instructor with reference to the standard operating procedure (SOP) for a 12-week
 course of 1 hour twice a week. The evaluation points were 0, 4, 8, and 12 weeks. The change
 of pain Visual Analogue Score (VAS) and tener point count (TPC) post-treatment were
 evaluated. And blood, feces, and brain fMRI were collected from the patients at 0 and 12
 weeks to compare the changes in gut microbiota, metabolites, and brain function networks
 before and after the intervention with the 16SrRNA sequencing, targeted metabolomics, and
 real-time Quantitative Polymerase Chain Reaction (PCR).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06410430
Non-Device Trial